Virginia Tech researchers have shown that memory loss in aging may be reversible. Using CRISPR tools, they corrected molecular disruptions in the hippocampus and amygdala, restoring memory in older ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...

A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...